Start,End,Entity,Semantic,File Name
34,53,alzheimer's disease,condition,NCT00000178
33,61,probably alzheimer's disease,condition,NCT00141661
66,81,at least 1 year,time,NCT00141661
75,76,1,value,NCT00141661
83,118,mini mental state exam (mmse) score,measurement,NCT00141661
127,132,12-26,value,NCT00141661
180,204,cholinesterase inhibitor,drug,NCT00141661
212,221,memantine,drug,NCT00141661
226,243,at least 4 months,time,NCT00141661
235,236,4,value,NCT00141661
270,287,at least 2 months,time,NCT00141661
43,63,probable alzheimer's,condition,NCT00151502
132,175,mini-mental status examination score (mmse),measurement,NCT00151502
200,207,13 - 25,value,NCT00151502
42,61,alzheimer's disease,condition,NCT00191009
109,133,mini mental status score,measurement,NCT00191009
142,151,10 and 26,value,NCT00191009
182,191,caregiver,caregiver,NCT00191009
195,220,frequent or daily contact,time,NCT00191009
313,329,alzheimer's drug,drug,NCT00191009
344,361,at least 3 months,time,NCT00191009
20,44,diagnosis of probable ad,value,NCT00205179
33,44,probable ad,condition,NCT00205179
72,81,caregiver,caregiver,NCT00205179
145,169,cholinesterase inhibitor,drug,NCT00205179
154,158,male,demography,NCT00217763
170,173,age,demography,NCT00217763
174,192,50 years and older,value,NCT00217763
195,304,female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal),condition,NCT00217763
271,287,at least 2 years,time,NCT00217763
319,339,probable alzheimer's,condition,NCT00217763
526,534,dementia,condition,NCT00217763
581,617,mini mental state examination (mmse),measurement,NCT00217763
668,691,living in the community,demography,NCT00217763
708,717,caregiver,caregiver,NCT00217763
719,825,participant living in an assisted living facility may be included if study medication intake is supervised,demography,NCT00217763
914,944,acetylcholinesterase inhibitor,drug,NCT00217763
946,955,donepezil,drug,NCT00217763
957,968,galantamine,drug,NCT00217763
972,984,rivastigmine,drug,NCT00217763
1017,1034,at least 4 months,time,NCT00217763
1026,1027,4,value,NCT00217763
1118,1132,not have taken,time,NCT00217763
1133,1142,memantine,drug,NCT00217763
1423,1443,legal representative,caregiver,NCT00217763
59,87,moderate alzheimer's disease,condition,NCT00224497
150,154,mmse,measurement,NCT00224497
164,169,12-24,value,NCT00224497
190,200,caregivers,caregiver,NCT00224497
281,291,laboratory,measurement,NCT00224497
74,99,mild cognitive impairment,condition,NCT00236431
100,126,delayed recall score <= 10,value,NCT00236431
132,173,new york university paragraph recall test,measurement,NCT00236431
321,330,informant,caregiver,NCT00236431
74,99,mild cognitive impairment,condition,NCT00236574
100,145,delayed recall score less than or equal to 10,value,NCT00236574
149,190,new york university paragraph recall test,measurement,NCT00236574
339,348,informant,caregiver,NCT00236574
22,30,dementia,condition,NCT00255086
54,65,50-95 years,value,NCT00255086
69,72,age,demography,NCT00255086
87,91,mmse,measurement,NCT00255086
115,119,7-28,value,NCT00255086
131,132,4,value,NCT00255086
160,169,caregiver,caregiver,NCT00255086
170,183,study partner,caregiver,NCT00255086
23,27,male,demography,NCT00265148
48,59,one or more,value,NCT00265148
222,225,age,demography,NCT00265148
391,401,laboratory,measurement,NCT00265148
847,866,alzheimer's disease,condition,NCT00265148
982,990,relative,caregiver,NCT00265148
1103,1139,mini mental state examination (mmse),measurement,NCT00265148
1149,1154,16-26,value,NCT00265148
1182,1186,aged,demography,NCT00265148
1187,1203,>/= 50 to </= 85,value,NCT00265148
1386,1395,caregiver,caregiver,NCT00265148
1556,1615,subjects living alone or in a nursing home are not eligible,demography,NCT00265148
33,53,probable alzheimer's,condition,NCT00277810
77,101,cholinesterase inhibitor,drug,NCT00277810
153,163,lives with,time,NCT00277810
176,185,caregiver,caregiver,NCT00277810
186,193,at home,demography,NCT00277810
290,304,at least daily,time,NCT00277810
20,31,outpatients,demography,NCT00309725
47,66,alzheimer's disease,condition,NCT00309725
247,267,probable alzheimer's,condition,NCT00309725
290,298,dementia,condition,NCT00309725
317,353,mini-mental state examination (mmse),measurement,NCT00309725
360,392,"ranging from 11 to 24, inclusive",value,NCT00309725
499,516,at least 6 months,time,NCT00309725
621,633,at least one,value,NCT00309725
837,842,daily,time,NCT00309725
855,866,one or more,value,NCT00309725
879,888,caregiver,caregiver,NCT00309725
1415,1423,relative,caregiver,NCT00309725
1437,1457,legal representative,caregiver,NCT00309725
20,126,the patient must have successfully completed the full 78-week duration of the double-blind cl-758007 study,condition,NCT00314912
128,132,male,demography,NCT00314912
144,147,age,demography,NCT00314912
148,166,50 years and older,value,NCT00314912
169,278,female must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal),condition,NCT00314912
245,261,at least 2 years,time,NCT00314912
296,319,living in the community,demography,NCT00314912
336,345,caregiver,caregiver,NCT00314912
347,453,participant living in an assisted living facility may be included if study medication intake is supervised,demography,NCT00314912
529,563,reasonably good nutritional status,condition,NCT00314912
607,627,legal representative,caregiver,NCT00314912
120,124,male,demography,NCT00348140
163,165,no,value,NCT00348140
172,192,probable alzheimer's,condition,NCT00348140
227,229,ad,condition,NCT00348140
426,462,mild to moderate alzheimer's disease,condition,NCT00348140
479,483,mmse,measurement,NCT00348140
490,498,10 to 26,value,NCT00348140
523,547,hachinski ischemia score,measurement,NCT00348140
548,551,≤ 4,value,NCT00348140
583,586,age,demography,NCT00348140
587,604,≥50 and ≤90 years,value,NCT00348140
606,623,at least 6 months,time,NCT00348140
635,665,acetylcholinesterase inhibitor,drug,NCT00348140
704,748,stable dosing for at least the last 2 months,time,NCT00348140
928,1077,"female subjects must be post-menopausal (i.e. >1 year without menstrual period), surgically sterile, or agree to use adequate method of contraception",condition,NCT00348140
1146,1286,"pre-menopausal or who have been post-menopausal for <1 year must undertake pregnancy testing (urine test) at visit 1, which must be negative",condition,NCT00348140
1288,1303,brain ct or mri,procedure,NCT00348140
1300,1303,mri,measurement,NCT00348140
1370,1453,no evidence of any other potential cause of dementia other than alzheimer's disease,value,NCT00348140
1414,1422,dementia,condition,NCT00348140
1572,1589,neurological exam,procedure,NCT00348140
1764,1774,lives with,time,NCT00348140
1830,1839,caregiver,caregiver,NCT00348140
2695,2770,"no less than 10 hours per week with the subject, divided over multiple days",time,NCT00348140
3398,3473,qtc (either qtc b (bazett's correction) or qtc f (fridericia's correction)),measurement,NCT00348140
3474,3482,<450msec,value,NCT00348140
3517,3582,subjects with bundle branch block (for whom either qtc b or qtc f,measurement,NCT00348140
3591,3599,<480msec,value,NCT00348140
153,157,male,demography,NCT00357357
169,172,age,demography,NCT00357357
173,186,over 55 years,value,NCT00357357
189,233,females must be non-child-bearing potential.,condition,NCT00357357
234,361,male patients with female partners of child-bearing potential should use effective contraception for the duration of the study.,condition,NCT00357357
377,397,probable alzheimer's,condition,NCT00357357
613,621,dementia,condition,NCT00357357
661,697,mini-mental state examination (mmse),measurement,NCT00357357
707,712,12-24,value,NCT00357357
731,754,living in the community,demography,NCT00357357
775,789,at least daily,time,NCT00357357
816,821,carer,caregiver,NCT00357357
37,56,alzheimer's disease,condition,NCT00380302
64,158,brain image(computerized axial tomographic scan -cat scan or magnetic resonance imaging - mri),procedure,NCT00380302
154,157,mri,measurement,NCT00380302
20,24,male,demography,NCT00381238
64,158,completed the 12 month visit of 49653/461 (12 months of treatment) without tolerability issues,condition,NCT00381238
278,587,"female subjects must be post-menopausal (i.e. >6 months without menstrual period), surgically sterile, or if of child-bearing potential, using effective contraceptive measures (oral contraceptives, norplant, depo-provera, an intra-uterine device (iud) a diaphragm with spermicide or a condom with spermicide).",condition,NCT00381238
324,333,>6 months,time,NCT00381238
759,768,caregiver,caregiver,NCT00381238
20,37,at least 60 years,value,NCT00384423
38,41,old,demography,NCT00384423
55,60,10 mg,value,NCT00384423
69,76,aricept,drug,NCT00384423
81,97,at least 90 days,time,NCT00384423
147,167,probable alzheimer's,condition,NCT00384423
182,190,dementia,condition,NCT00384423
274,341,"not pregnant, planning a pregnancy, or capable of becoming pregnant",condition,NCT00384423
33,35,no,value,NCT00428090
42,62,probable alzheimer's,condition,NCT00428090
72,74,ad,condition,NCT00428090
77,81,mmse,measurement,NCT00428090
88,96,10 to 23,value,NCT00428090
195,201,acheis,drug,NCT00428090
217,226,caregiver,caregiver,NCT00428090
20,23,age,demography,NCT00438568
24,37,55 or greater,value,NCT00438568
97,122,mild cognitive impairment,condition,NCT00438568
132,151,alzheimer's disease,condition,NCT00438568
153,155,ad,condition,NCT00438568
189,198,memantine,drug,NCT00438568
212,237,cholinesterase inhibitors,drug,NCT00438568
67,70,age,demography,NCT00478205
94,108,45 to 90 years,value,NCT00478205
132,141,caregiver,caregiver,NCT00478205
20,34,female or male,demography,NCT00500500
38,52,50 to 85 years,value,NCT00500500
53,56,old,demography,NCT00500500
64,74,care giver,caregiver,NCT00500500
75,99,mini mental status (mms),measurement,NCT00500500
113,121,16 to 26,value,NCT00500500
132,156,clinical dementia rating,measurement,NCT00500500
141,149,dementia,condition,NCT00500500
158,161,cdr,measurement,NCT00500500
168,190,inferior or equal to 1,value,NCT00500500
267,286,alzheimer's disease,condition,NCT00500500
341,349,positive,value,NCT00500500
40,59,alzheimer's disease,condition,NCT00581867
20,24,male,demography,NCT00663936
28,73,female (post-menopausal or surgically sterile,condition,NCT00663936
89,125,mild to moderate alzheimer's disease,condition,NCT00663936
144,153,donepezil,drug,NCT00663936
155,158,age,demography,NCT00663936
159,167,50 to 90,value,NCT00663936
195,218,living in the community,demography,NCT00663936
250,259,informant,caregiver,NCT00663936
263,276,study partner,caregiver,NCT00663936
278,287,caregiver,caregiver,NCT00663936
0,12,men or women,demography,NCT00672945
29,53,diagnosis of probable ad,value,NCT00672945
42,53,probable ad,condition,NCT00672945
54,58,mmse,measurement,NCT00672945
65,73,12 to 22,value,NCT00672945
84,87,age,demography,NCT00672945
88,105,>50 and <90 years,value,NCT00672945
115,132,at least 4 months,time,NCT00672945
124,125,4,value,NCT00672945
153,162,donepezil,drug,NCT00672945
163,167,10mg,value,NCT00672945
178,193,brain ct or mri,procedure,NCT00672945
190,193,mri,measurement,NCT00672945
241,257,within 24 months,time,NCT00672945
258,282,neurological examination,procedure,NCT00672945
283,412,"without focal deficits (excluding changes attributable to peripheral nervous system disease, trauma or congenital birth deficits)",value,NCT00672945
413,510,no history or evidence of any other cns disorder that could be interpreted as a cause of dementia,condition,NCT00672945
511,544,no diagnosis of vascular dementia,condition,NCT00672945
545,642,no history of significant psychiatric illness such as schizophrenia or bipolar affective disorder,condition,NCT00672945
707,721,antidepressant,drug,NCT00672945
726,735,>6 months,time,NCT00672945
752,897,"no evidence of the following: current vitamin b12 deficiency, positive syphilis serology, positive hiv test, or abnormalities in thyroid function",condition,NCT00672945
814,822,positive,value,NCT00672945
898,925,no cognitive rehabilitation,condition,NCT00672945
926,941,within 6 months,time,NCT00672945
977,986,caregiver,caregiver,NCT00672945
1097,1132,no history of drug or alcohol abuse,condition,NCT00672945
1133,1158,no clinically significant,value,NCT00672945
1159,1169,laboratory,measurement,NCT00672945
1274,1283,memantine,drug,NCT00672945
1284,1299,within 2 months,time,NCT00672945
1336,1367,acetylcholinesterase inhibitors,drug,NCT00672945
1398,1413,within 4 months,time,NCT00672945
1454,1457,ecg,procedure,NCT00672945
1475,1490,cardiac history,condition,NCT00672945
1491,1534,no history of uncontrolled seizure disorder,condition,NCT00672945
1535,1551,within 12 months,time,NCT00672945
1583,1597,mao inhibitors,drug,NCT00672945
1599,1608,bupropion,drug,NCT00672945
1609,1619,fluoxetine,drug,NCT00672945
1621,1631,paroxetine,drug,NCT00672945
1643,1667,no history of malignancy,condition,NCT00672945
1668,1682,within 3 years,time,NCT00672945
1700,1741,women cannot be pregnant or breastfeeding,condition,NCT00672945
20,44,diagnosis of probable ad,value,NCT00676143
33,44,probable ad,condition,NCT00676143
51,55,mmse,measurement,NCT00676143
65,70,16-26,value,NCT00676143
76,85,brain mri,procedure,NCT00676143
82,85,mri,measurement,NCT00676143
86,121,consistent with the diagnosis of ad,value,NCT00676143
140,164,cholinesterase inhibitor,drug,NCT00676143
168,177,memantine,drug,NCT00676143
198,207,caregiver,caregiver,NCT00676143
42,52,either sex,demography,NCT00684944
81,86,carer,caregiver,NCT00684944
499,519,legal representative,caregiver,NCT00684944
588,654,must have been ongoing in trx-014-001 at time of study termination,condition,NCT00684944
20,32,men or women,demography,NCT00693004
49,73,diagnosis of probable ad,value,NCT00693004
62,73,probable ad,condition,NCT00693004
74,78,mmse,measurement,NCT00693004
85,93,16 to 24,value,NCT00693004
104,107,age,demography,NCT00693004
108,125,>50 and <90 years,value,NCT00693004
126,141,brain ct or mri,procedure,NCT00693004
138,141,mri,measurement,NCT00693004
189,205,within 12 months,time,NCT00693004
206,230,neurological examination,procedure,NCT00693004
231,360,"without focal deficits (excluding changes attributable to peripheral nervous system disease, trauma or congenital birth deficits)",value,NCT00693004
361,458,no history or evidence of any other cns disorder that could be interpreted as a cause of dementia,condition,NCT00693004
459,492,no diagnosis of vascular dementia,condition,NCT00693004
493,590,no history of significant psychiatric illness such as schizophrenia or bipolar affective disorder,condition,NCT00693004
655,669,antidepressant,drug,NCT00693004
674,683,>6 months,time,NCT00693004
700,845,"no evidence of the following: current vitamin b12 deficiency, positive syphilis serology, positive hiv test, or abnormalities in thyroid function",condition,NCT00693004
762,770,positive,value,NCT00693004
846,873,no cognitive rehabilitation,condition,NCT00693004
874,889,within 6 months,time,NCT00693004
925,934,caregiver,caregiver,NCT00693004
20,62,giving informed consent to lumbar puncture,condition,NCT00715858
47,62,lumbar puncture,procedure,NCT00715858
148,168,probable alzheimer's,condition,NCT00715858
177,182,smmse,measurement,NCT00715858
183,188,14-26,value,NCT00715858
218,221,age,demography,NCT00715858
222,235,50 or greater,value,NCT00715858
236,245,caregiver,caregiver,NCT00715858
310,374,adequate english literacy to complete neuropsychological testing,condition,NCT00715858
375,407,generally stable level of health,condition,NCT00715858
113,132,alzheimer's disease,condition,NCT00785759
175,177,ad,condition,NCT00785759
206,217,probable ad,condition,NCT00785759
226,228,no,value,NCT00785759
311,319,dementia,condition,NCT00785759
381,393,amnestic mci,condition,NCT00785759
411,465,no evidence of cognitive impairment by medical history,condition,NCT00785759
20,56,mild to moderate alzheimer's disease,condition,NCT00930059
58,62,mmse,measurement,NCT00930059
63,68,14-26,value,NCT00930059
70,89,good general health,condition,NCT00930059
20,37,early stage of ad,condition,NCT00951834
28,31,age,demography,NCT00951834
43,45,no,value,NCT00951834
100,106,60-100,value,NCT00951834
107,111,mmse,measurement,NCT00951834
112,117,20-26,value,NCT00951834
132,139,at home,demography,NCT00951834
145,157,at least one,value,NCT00951834
158,166,relative,caregiver,NCT00951834
226,235,donepezil,drug,NCT00951834
237,244,aricept,drug,NCT00951834
267,309,with at least 3 months to maximum 6 months,time,NCT00951834
340,374,maximum of 2 cups of black tea/die,condition,NCT00951834
376,388,no green tea,condition,NCT00951834
390,436,not more than > 500 ml/die of grapefruit juice,condition,NCT00951834
20,37,55 years or older,value,NCT01058941
38,49,probable ad,condition,NCT01058941
127,146,alzheimer's disease,condition,NCT01058941
205,209,mmse,measurement,NCT01058941
218,223,15-26,value,NCT01058941
224,233,caregiver,caregiver,NCT01058941
234,247,study partner,caregiver,NCT01058941
313,338,cholinesterase inhibitors,drug,NCT01058941
343,352,memantine,drug,NCT01058941
390,404,4 months prior,time,NCT01058941
390,391,4,value,NCT01058941
441,502,"over-the-counter antioxidants (e.g. vitamin e, ginkgo biloba)",drug,NCT01058941
593,618,lipid lowering medication,drug,NCT01058941
680,706,geriatric depression scale,measurement,NCT01058941
724,727,< 5,value,NCT01058941
838,848,laboratory,measurement,NCT01058941
856,876,within normal limits,value,NCT01058941
29,33,aged,demography,NCT01075763
42,57,50 and 75 years,value,NCT01075763
82,84,ad,condition,NCT01075763
193,197,mmse,measurement,NCT01075763
207,215,20 to 26,value,NCT01075763
253,262,caregiver,caregiver,NCT01075763
42,70,probable alzheimer´s disease,condition,NCT01125683
71,96,hachinski ischaemic score,measurement,NCT01125683
97,100,< 4,value,NCT01125683
101,110,mse score,measurement,NCT01125683
111,119,18 to 24,value,NCT01125683
42,62,probable alzheimer's,condition,NCT01183806
71,88,at least 55 years,value,NCT01183806
92,95,age,demography,NCT01183806
101,110,caregiver,caregiver,NCT01183806
138,155,at least 3 months,time,NCT01183806
138,162,at least 3 months before,value,NCT01183806
233,299,do not be taking other prescribed medication for alzheimer disease,drug,NCT01183806
300,327,treated stable hypertension,condition,NCT01183806
20,24,male,demography,NCT01245530
36,39,age,demography,NCT01245530
60,63,old,demography,NCT01245530
112,132,legal representative,caregiver,NCT01245530
157,176,alzheimer's disease,condition,NCT01245530
230,250,probable alzheimer's,condition,NCT01245530
425,429,mmse,measurement,NCT01245530
436,444,10 to 26,value,NCT01245530
445,480,cdr(clinical dementia rating) score,measurement,NCT01245530
458,466,dementia,condition,NCT01245530
488,519,gds(global deterioration scale),measurement,NCT01245530
543,554,didn't take,value,NCT01245530
574,579,achei,drug,NCT01245530
581,590,donepezil,drug,NCT01245530
592,601,memantine,drug,NCT01245530
603,613,galantamin,drug,NCT01245530
659,686,at least 4 weeks more prior,time,NCT01245530
668,669,4,value,NCT01245530
715,730,menopause women,condition,NCT01245530
734,830,her/his spouse consent with contraception during the study period and 90 days after end of study,condition,NCT01245530
42,62,probable alzheimer's,condition,NCT01249196
89,91,ad,condition,NCT01249196
105,108,mri,measurement,NCT01249196
105,108,mri,procedure,NCT01249196
125,126,1,value,NCT01249196
135,168,consistent with a diagnosis of ad,value,NCT01249196
169,173,mmse,measurement,NCT01249196
183,191,10 to 26,value,NCT01249196
196,199,cdr,measurement,NCT01249196
203,209,1 or 2,value,NCT01249196
210,215,achei,drug,NCT01249196
219,228,memantine,drug,NCT01249196
233,266,not taken at least 3 months prior,time,NCT01249196
33,83,amnestic or non-amnestic mild cognitive impairment,condition,NCT01303744
85,120,mini-mental state examination score,measurement,NCT01303744
121,135,higher than 24,value,NCT01303744
150,153,mri,measurement,NCT01303744
150,153,mri,procedure,NCT01303744
149,158,caregiver,caregiver,NCT01324518
159,180,males and and females,demography,NCT01324518
189,194,55-90,value,NCT01324518
214,234,probable alzheimer's,condition,NCT01324518
291,304,brain imaging,procedure,NCT01324518
305,340,consistent with alzheimer's disease,value,NCT01324518
341,376,mini-mental state examination score,measurement,NCT01324518
377,382,12-21,value,NCT01324518
396,405,donepezil,drug,NCT01324518
407,419,rivastigmine,drug,NCT01324518
423,434,galantamine,drug,NCT01324518
20,23,age,demography,NCT01409694
24,34,≥ 60 years,value,NCT01409694
39,41,no,value,NCT01409694
48,76,moderate alzheimer's disease,condition,NCT01409694
135,171,mini-mental state examination (mmse),measurement,NCT01409694
172,201,between 10 and 20 inclusively,value,NCT01409694
210,293,"hypovitaminosis d (i.e., serum 25-hydroxyvitamin d [25ohd]concentration < 30 ng/ml)",condition,NCT01409694
302,373,"no hypercalcemia (defined as serum calcium concentration ≥ 2,65 mmol/l)",condition,NCT01409694
514,534,legal representative,caregiver,NCT01409694
20,24,male,demography,NCT01436045
59,83,diagnosis of probable ad,value,NCT01436045
72,83,probable ad,condition,NCT01436045
185,204,alzheimer's disease,condition,NCT01436045
267,275,dementia,condition,NCT01436045
298,299,1,value,NCT01436045
301,302,4,value,NCT01436045
305,341,mini-mental state examination (mmse),measurement,NCT01436045
351,356,18-26,value,NCT01436045
358,382,hachinski ischemia score,measurement,NCT01436045
383,386,< 4,value,NCT01436045
388,391,age,demography,NCT01436045
395,413,> 65 and <85 years,value,NCT01436045
414,477,females must be > 2 years post-menopausal or surgically sterile,condition,NCT01436045
630,655,"family member /caregiver,",caregiver,NCT01436045
1002,1035,legally authorized representative,caregiver,NCT01436045
1055,1065,≥ 1 months,time,NCT01436045
1083,1113,acetylcholinesterase inhibitor,drug,NCT01436045
1120,1129,donepezil,drug,NCT01436045
1131,1143,rivastigmine,drug,NCT01436045
1145,1156,galantamine,drug,NCT01436045
1165,1174,memantine,drug,NCT01436045
1178,1193,brain ct or mri,procedure,NCT01436045
1190,1193,mri,measurement,NCT01436045
1214,1275,compatible with the diagnosis of probable alzheimer's disease,value,NCT01436045
1247,1267,probable alzheimer's,condition,NCT01436045
1279,1303,clinical dementia rating,measurement,NCT01436045
1305,1308,cdr,measurement,NCT01436045
1323,1329,1 to 2,value,NCT01436045
44,46,ad,condition,NCT01466088
114,150,mini-mental state examination (mmse),measurement,NCT01466088
161,169,12 to 22,value,NCT01466088
184,208,at least 12 months prior,time,NCT01466088
240,253,brain imaging,procedure,NCT01466088
262,277,within 6 months,time,NCT01466088
318,326,dementia,condition,NCT01466088
370,388,modified hachinski,measurement,NCT01466088
413,419,</= 4.,value,NCT01466088
434,443,caregiver,caregiver,NCT01466088
571,587,able to complete,value,NCT01466088
23,25,no,value,NCT01539031
53,73,probable alzheimer's,condition,NCT01539031
83,85,ad,condition,NCT01539031
202,238,mini mental state examination (mmse),measurement,NCT01539031
239,293,less than or equal to 12 and greater than or equal to1,value,NCT01539031
409,461,no evidence of focal disease to account for dementia,value,NCT01539031
453,461,dementia,condition,NCT01539031
479,482,age,demography,NCT01539031
484,510,magnetic resonance imaging,procedure,NCT01539031
512,515,mri,measurement,NCT01539031
512,515,mri,procedure,NCT01539031
566,570,male,demography,NCT01539031
591,624,greater than or equal to 50 years,value,NCT01539031
642,653,outpatients,demography,NCT01539031
719,728,caregiver,caregiver,NCT01539031
873,882,donepezil,drug,NCT01539031
891,896,10 mg,value,NCT01539031
917,922,daily,time,NCT01539031
932,965,greater than or equal to 3 months,time,NCT01539031
29,53,diagnosis of probable ad,value,NCT01569516
42,53,probable ad,condition,NCT01569516
101,105,male,demography,NCT01569516
121,125,aged,demography,NCT01569516
134,143,50 and 85,value,NCT01569516
145,173,mild to moderate probable ad,condition,NCT01569516
175,273,"middle school or above: 11 ≤mmse ≤ 25, elementary school: 8 ≤ mmse ≤ 20, illiteracy: 5 ≤ mmse ≤ 16",value,NCT01569516
203,207,mmse,measurement,NCT01569516
275,289,ct or mri scan,procedure,NCT01569516
281,284,mri,measurement,NCT01569516
290,332,excluding another structural brain disease,value,NCT01569516
346,368,neurologic examination,procedure,NCT01569516
369,397,no significant abnormalities,value,NCT01569516
399,423,hachinski ischemic score,measurement,NCT01569516
454,457,≤10,value,NCT01569516
459,475,able to complete,value,NCT01569516
588,597,chaperone,caregiver,NCT01569516
599,692,more than 2 hours a day together with the patient or accumulated fewer than 14 hours per week,time,NCT01569516
730,750,legal representative,caregiver,NCT01569516
763,772,caregiver,caregiver,NCT01569516
38,47,caregiver,caregiver,NCT01676935
308,374,randomized into study m10-985 and completed dosing through week 24,condition,NCT01676935
429,448,mild to moderate ad,condition,NCT01676935
578,598,physical examination,procedure,NCT01676935
600,611,vital signs,measurement,NCT01676935
613,623,laboratory,measurement,NCT01676935
639,650,12-lead ecg,procedure,NCT01676935
657,834,"male, the subject is surgically sterile (vasectomy, is sexually inactive, or is using a barrier method of birth control (condom) with spermicidal foam/gel/film/cream/suppository",condition,NCT01676935
657,661,male,demography,NCT01676935
968,1028,postmenopausal for at least 2 years or is surgically sterile,condition,NCT01676935
987,1003,at least 2 years,time,NCT01676935
244,253,caregiver,caregiver,NCT01723826
300,305,daily,time,NCT01723826
391,411,probable alzheimer's,condition,NCT01723826
609,645,mini-mental state examination (mmse),measurement,NCT01723826
655,665,10 or more,value,NCT01723826
706,833,"male participants with partners with reproductive potential, agreement to use a reliable means of contraception (e.g., condoms)",condition,NCT01723826
706,710,male,demography,NCT01723826
918,964,"female participants, a negative pregnancy test",condition,NCT01723826
62,66,amci,condition,NCT01767909
91,102,probable ad,condition,NCT01767909
179,198,alzheimer's disease,condition,NCT01767909
257,293,mini mental state examination (mmse),measurement,NCT01767909
316,343,greater than or equal to 20,value,NCT01767909
344,368,clinical dementia rating,measurement,NCT01767909
353,361,dementia,condition,NCT01767909
372,375,0.5,value,NCT01767909
376,377,1,value,NCT01767909
457,466,education,demography,NCT01767909
468,491,less than or equal to 4,value,NCT01767909
688,704,able to complete,value,NCT01767909
726,744,modified hachinski,measurement,NCT01767909
780,793,study partner,caregiver,NCT01767909
950,1005,more than 2 days per week (minimum of 10 hours per week,value,NCT01767909
1089,1101,for 3 months,time,NCT01767909
1150,1157,4 weeks,time,NCT01767909
1237,1284,at least six years of education or work history,demography,NCT01767909
1294,1304,laboratory,measurement,NCT01767909
1320,1340,within normal limits,value,NCT01767909
20,44,diagnosis of probable ad,value,NCT01852110
33,44,probable ad,condition,NCT01852110
139,158,alzheimer's disease,condition,NCT01852110
428,440,at least one,value,NCT01852110
530,539,informant,caregiver,NCT01852110
597,602,daily,time,NCT01852110
611,616,achei,drug,NCT01852110
625,634,donepezil,drug,NCT01852110
636,648,rivastigmine,drug,NCT01852110
653,664,galantamine,drug,NCT01852110
671,690,at least two months,value,NCT01852110
828,833,10 mg,value,NCT01852110
886,991,9.5 or 13.3 mg/24 hours administered by transdermal patch or 6-12 mg total daily dose administered orally,value,NCT01852110
1006,1031,16-24 mg total daily dose,value,NCT01852110
1117,1207,history of academic achievement and/or employment sufficient to exclude mental retardation,condition,NCT01852110
1238,1251,trial partner,caregiver,NCT01852110
53,57,male,demography,NCT01940952
77,85,50 to 90,value,NCT01940952
95,98,age,demography,NCT01940952
113,133,probable alzheimer's,condition,NCT01940952
300,336,mini-mental state examination (mmse),measurement,NCT01940952
346,357,≥10 and ≤26,value,NCT01940952
366,390,clinical dementia rating,measurement,NCT01940952
375,383,dementia,condition,NCT01940952
391,396,≥ 0.5,value,NCT01940952
398,457,mild to moderate (not severe) white matter hyperintensities,value,NCT01940952
461,470,brain mri,procedure,NCT01940952
467,470,mri,measurement,NCT01940952
593,603,caregivers,caregiver,NCT01940952
604,674,living with patients or spending 10 or more hours a week with patients,value,NCT01940952
691,700,donepezil,drug,NCT01940952
701,713,(5mg to 10mg,value,NCT01940952
719,735,at least 60 days,time,NCT01940952
762,771,memantine,drug,NCT01940952
786,817,washed out for at least 60 days,time,NCT01940952
841,852,anxiolytics,drug,NCT01940952
854,868,antipsychotics,drug,NCT01940952
874,883,hypnotics,drug,NCT01940952
904,947,dose has been stable for at least two weeks,time,NCT01940952
20,70,membership in psen1 e280a mutation carrier kindred,condition,NCT01998841
38,39,1,value,NCT01998841
123,138,genetic testing,measurement,NCT01998841
178,182,apoe,measurement,NCT01998841
225,275,psen1 e280a mutation carrier or non-carrier status,value,NCT01998841
335,371,mini-mental stage examination (mmse),measurement,NCT01998841
372,525,greater than or equal to (>=) 24 for participants with less than (<) 9 years of education or mmse >=26 for participants with 9 or more years of education,value,NCT01998841
452,461,education,demography,NCT01998841
526,571,does not meet criteria for dementia due to ad,condition,NCT01998841
681,749,does not meet criteria for mild cognitive impairment (mci) due to ad,condition,NCT01998841
923,939,able to complete,value,NCT01998841
1404,1416,at least one,value,NCT01998841
1657,1858,"men with partners of childbearing potential (that is [i.e.], women who are not surgically sterile and are not postmenopausal), agreement to remain abstinent or use a condom as a method of contraception",condition,NCT01998841
1946,1959,study partner,caregiver,NCT01998841
2410,2415,daily,time,NCT01998841
2890,2915,neuroimaging (pet and mri,procedure,NCT01998841
2912,2915,mri,measurement,NCT01998841
2917,2956,serum thyroid stimulating hormone (tsh),measurement,NCT01998841
2961,2971,b12 levels,measurement,NCT01998841
2979,2985,normal,value,NCT01998841
3021,3031,laboratory,measurement,NCT01998841
3665,3684,good general health,condition,NCT01998841
20,23,age,demography,NCT02017340
31,33,ad,condition,NCT02017340
47,64,males and females,demography,NCT02017340
65,82,over age 50 years,value,NCT02017340
103,131,mild to moderate probable ad,condition,NCT02017340
184,240,standardised mini-mental state examination (smmse) score,measurement,NCT02017340
241,245,> 12,value,NCT02017340
262,271,>3 months,time,NCT02017340
275,299,cholinesterase inhibitor,drug,NCT02017340
307,316,memantine,drug,NCT02017340
343,368,cholinesterase inhibitors,drug,NCT02017340
527,537,informants,caregiver,NCT02017340
930,967,systolic bp > 100 mmhg but ≤ 159 mmhg,value,NCT02017340
973,1009,diastolic bp > 65 mmhg but ≤ 99 mmhg,value,NCT02017340
1013,1049,resting office based bp measurements,measurement,NCT02017340
1056,1093,systolic bp > 105 mmhg but ≤ 140 mmhg,value,NCT02017340
1099,1135,diastolic bp > 70 mmhg but ≤ 90 mmhg,value,NCT02017340
1139,1155,abpm measurement,measurement,NCT02017340
27,29,ad,condition,NCT02033941
46,57,probable ad,condition,NCT02033941
58,62,mmse,measurement,NCT02033941
71,76,12-26,value,NCT02033941
94,118,cholinesterase inhibitor,drug,NCT02033941
125,162,nmda (n-methyl-d-asparate) antagonist,drug,NCT02033941
184,201,at least 12 weeks,time,NCT02033941
259,268,caregiver,caregiver,NCT02033941
353,362,informant,caregiver,NCT02033941
392,409,medical stability,value,NCT02033941
460,485,internist's physical exam,procedure,NCT02033941
487,504,neurological exam,procedure,NCT02033941
510,520,laboratory,measurement,NCT02033941
543,545,no,value,NCT02033941
567,603,no evidence of hepatic insufficiency,value,NCT02033941
20,24,aged,demography,NCT02035982
25,34,>55 years,value,NCT02035982
101,130,primary degenerative dementia,condition,NCT02035982
214,233,alzheimer's disease,condition,NCT02035982
276,278,ad,condition,NCT02035982
296,307,probable ad,condition,NCT02035982
311,339,at least one year's duration,time,NCT02035982
311,323,at least one,value,NCT02035982
346,349,≤15,value,NCT02035982
357,393,mini-mental state examination (mmse),measurement,NCT02035982
422,431,donepezil,drug,NCT02035982
433,443,5 or 10 mg,value,NCT02035982
446,457,galantamine,drug,NCT02035982
459,473,"8, 16 or 24 mg",value,NCT02035982
478,490,rivastigmine,drug,NCT02035982
492,506,"3, 4.5 or 6 mg",value,NCT02035982
517,533,at least 2 years,time,NCT02035982
558,575,at least 3 months,time,NCT02035982
658,670,psychotropic,drug,NCT02035982
810,824,antipsychotics,drug,NCT02035982
862,878,at least 1 month,time,NCT02035982
48,72,diagnosis of probable ad,value,NCT02064920
61,72,probable ad,condition,NCT02064920
143,152,informant,caregiver,NCT02064920
179,196,at least 6 months,time,NCT02064920
212,229,partner/caregiver,caregiver,NCT02064920
311,331,physical examination,procedure,NCT02064920
336,361,clinical laboratory tests,measurement,NCT02064920
369,375,normal,value,NCT02064920
641,701,acceptable history of academic achievement and/or employment,demography,NCT02064920
708,734,magnetic resonance imaging,procedure,NCT02064920
736,739,mri,measurement,NCT02064920
736,739,mri,procedure,NCT02064920
751,816,rules out non-ad conditions contributing to cognitive dysfunction,value,NCT02064920
905,946,females are not of childbearing potential,condition,NCT02064920
36,178,"completed visit 7 (completion visit) in the lead-in double-blind, placebo controlled clinical studies 14861a/nct01955161 or 14862a/nct02006641",condition,NCT02079246
225,264,completed visit 6 (week 28) of the olex,condition,NCT02079246
365,374,memantine,drug,NCT02079246
74,85,probable ad,condition,NCT02167256
86,106,18f-florbetapir scan,procedure,NCT02167256
86,87,1,value,NCT02167256
124,135,elevated aβ,value,NCT02167256
162,165,age,demography,NCT02167256
174,179,55-85,value,NCT02167256
192,196,mmse,measurement,NCT02167256
211,220,18 and 26,value,NCT02167256
272,279,4 weeks,time,NCT02167256
272,273,4,value,NCT02167256
312,327,antidepressants,drug,NCT02167256
390,392,no,value,NCT02167256
418,459,do not have a history of major depression,condition,NCT02167256
471,482,past 1 year,time,NCT02167256
484,509,cholinesterase inhibitors,drug,NCT02167256
514,523,memantine,drug,NCT02167256
552,566,12 weeks prior,time,NCT02167256
577,603,geriatric depression scale,measurement,NCT02167256
604,756,"less than 6 [note: a score ≥6 on this screening scale may be permissible, if the subject is examined by a site clinician and judged not to be depressed.",value,NCT02167256
758,771,study partner,caregiver,NCT02167256
834,862,average of 10 hours per week,value,NCT02167256
1023,1042,good general health,condition,NCT02167256
1096,1230,"subject is not pregnant, lactating, or of childbearing potential (i.e., women must be two years post-menopausal or surgically sterile)",condition,NCT02167256
1231,1249,modified hachinski,measurement,NCT02167256
1250,1273,less than or equal to 4,value,NCT02167256
1274,1294,completed six grades,value,NCT02167256
1298,1307,education,demography,NCT02167256
1311,1334,has a good work history,demography,NCT02167256
22,24,ad,condition,NCT02245737
93,111,more than 6 months,time,NCT02245737
141,154,study partner,caregiver,NCT02245737
155,190,mini-mental state examination score,measurement,NCT02245737
194,199,20-30,value,NCT02245737
324,353,mild alzheimer's disease (ad),condition,NCT02245737
459,470,probable ad,condition,NCT02245737
490,503,mci due to ad,condition,NCT02245737
20,24,ages,demography,NCT02246075
25,42,≥55 and ≤85 years,value,NCT02246075
222,246,support person/caregiver,caregiver,NCT02246075
353,361,dementia,condition,NCT02246075
381,392,probable ad,condition,NCT02246075
488,507,alzheimer's disease,condition,NCT02246075
520,546,magnetic resonance imaging,procedure,NCT02246075
548,551,mri,measurement,NCT02246075
548,551,mri,procedure,NCT02246075
596,612,within 12 months,time,NCT02246075
603,604,1,value,NCT02246075
645,758,consistent with the diagnosis of dementia due to ad without any other clinically significant comorbid pathologies,value,NCT02246075
766,780,mri or ct scan,measurement,NCT02246075
1023,1059,mini-mental state examination (mmse),measurement,NCT02246075
1066,1077,≥12 and ≤26,value,NCT02246075
1091,1109,modified hachinski,measurement,NCT02246075
1138,1140,≤4,value,NCT02246075
1154,1249,"fertile, sexually active subjects (men and women) must use an effective method of contraception",condition,NCT02246075
1189,1202,men and women,demography,NCT02246075
1268,1629,"female subjects and the female partner of male subjects must be surgically sterile (hysterectomy or bilateral tubal ligation), postmenopausal for at least 1-year, or willing to practice adequate methods of contraception if of childbearing potential (defined as consistent use of combined effective methods of contraception [including at least 1 barrier method])",condition,NCT02246075
1270,1274,male,demography,NCT02246075
1823,1953,"living at home, senior residential setting, or an institutional setting without the need for continuous (ie, 24-hour) nursing care",demography,NCT02246075
2147,2156,memantine,drug,NCT02246075
2161,2178,at least 3 months,time,NCT02246075
2289,2294,achei,drug,NCT02246075
2296,2305,donepezil,drug,NCT02246075
2309,2350,any dose form other than 23 mg once daily,value,NCT02246075
2345,2350,daily,time,NCT02246075
2357,2369,rivastigmine,drug,NCT02246075
2373,2384,galantamine,drug,NCT02246075
20,233,completed the pivotal ad-4833/tomm40_301 study with an adjudicated diagnosis of mild cognitive impairment (mci) due to alzheimer's disease (ad) without ongoing serious adverse events (saes) from ad-4833/tomm40_301,condition,NCT02284906
238,242,male,demography,NCT02284906
260,277,at least 65 years,value,NCT02284906
281,284,age,demography,NCT02284906
664,718,living independently or in nonmedical residential care,demography,NCT02284906
726,741,project partner,caregiver,NCT02284906
217,230,mci due to ad,condition,NCT02322021
257,269,prodromal ad,condition,NCT02322021
274,285,ad dementia,condition,NCT02322021
296,299,age,demography,NCT02322021
360,376,amyloid positive,value,NCT02322021
377,411,positron emission tomography (pet),procedure,NCT02322021
457,461,male,demography,NCT02322021
477,491,50 to 85 years,value,NCT02322021
547,556,caregiver,caregiver,NCT02322021
560,569,informant,caregiver,NCT02322021
698,728,acetylcholinesterase inhibitor,drug,NCT02322021
730,735,achei,drug,NCT02322021
740,749,memantine,drug,NCT02322021
787,804,at least 12 weeks,time,NCT02322021
853,855,no,value,NCT02322021
1024,1030,acheis,drug,NCT02322021
1233,1246,least 4 weeks,time,NCT02322021
1239,1240,4,value,NCT02322021
37,48,45-89 years,value,NCT02380573
49,52,old,demography,NCT02380573
53,64,all genders,demography,NCT02380573
65,79,all minorities,demography,NCT02380573
123,172,postmenopausal or surgically sterile females only,condition,NCT02380573
244,273,amnestic and non-amnestic mci,condition,NCT02380573
395,397,ad,condition,NCT02380573
410,448,"alzheimer's early-stage, sporadic-type",condition,NCT02380573
40,70,early alzheimer's disease (ad),condition,NCT02406027
78,103,mild cognitive impairment,condition,NCT02423122
117,128,probable ad,condition,NCT02423122
135,142,mild ad,condition,NCT02423122
143,147,mmse,measurement,NCT02423122
155,163,20 to 28,value,NCT02423122
164,193,evidence of amyloid pathology,value,NCT02423122
197,208,amyloid pet,procedure,NCT02423122
241,259,medications for ad,drug,NCT02423122
325,334,>3 months,time,NCT02423122
50,59,caregiver,caregiver,NCT02431468
151,155,male,demography,NCT02431468
176,181,55-85,value,NCT02431468
191,194,age,demography,NCT02431468
235,251,at least 2 years,time,NCT02431468
290,310,probable alzheimer's,condition,NCT02431468
311,348,mini mental state exam (mmse-2) score,measurement,NCT02431468
352,353,4,value,NCT02431468
390,402,at least one,value,NCT02431468
447,526,neuroimaging (computerized tomography (ct) or magnetic resonance imaging (mri)),procedure,NCT02431468
521,524,mri,measurement,NCT02431468
553,617,consistent with a diagnosis of probable alzheimer's disease (ad),value,NCT02431468
584,612,probable alzheimer's disease,condition,NCT02431468
614,616,ad,condition,NCT02431468
627,655,caregiver(s) or informant(s),caregiver,NCT02431468
692,754,average of 3 hours or more per day for 3 or more days per week,time,NCT02431468
881,906,cholinesterase inhibitors,drug,NCT02431468
908,917,memantine,drug,NCT02431468
949,966,at least 3 months,time,NCT02431468
20,56,mean resting systolic blood pressure,measurement,NCT02471833
57,82,≥ 110 mmhg and ≤ 170 mmhg,value,NCT02471833
83,120,family history of alzheimer's disease,condition,NCT02471833
121,137,african american,demography,NCT02471833
77,90,mci due to ad,condition,NCT02484547
94,101,mild ad,condition,NCT02484547
119,143,clinical dementia rating,measurement,NCT02484547
128,136,dementia,condition,NCT02484547
166,169,0.5,value,NCT02484547
230,234,mmse,measurement,NCT02484547
249,258,24 and 30,value,NCT02484547
283,291,positive,value,NCT02484547
292,339,amyloid positron emission tomography (pet) scan,procedure,NCT02484547
374,378,apoe,measurement,NCT02484547
506,507,1,value,NCT02484547
529,538,informant,caregiver,NCT02484547
542,551,caregiver,caregiver,NCT02484547
39,50,body weight,measurement,NCT02576639
52,57,≥45kg,value,NCT02576639
58,61,bmi,measurement,NCT02576639
63,74,18-34 kg/m2,value,NCT02576639
47,67,probable alzheimer's,condition,NCT02579252
187,223,mini mental state examination (mmse),measurement,NCT02579252
230,243,≥ 20 and ≤ 26,value,NCT02579252
245,254,brain mri,procedure,NCT02579252
251,254,mri,measurement,NCT02579252
263,315,consistent with the diagnosis of alzheimer's disease,value,NCT02579252
316,415,medial temporal lobe atrophy: scheltens score of ≥ 2 (on a scale of 0-4 on the more atrophied side),value,NCT02579252
423,431,positive,value,NCT02579252
432,434,ad,condition,NCT02579252
460,463,csf,measurement,NCT02579252
465,479,"amyloid+, tau+",value,NCT02579252
481,497,at least 6 years,value,NCT02579252
501,528,formal elementary education,demography,NCT02579252
530,533,age,demography,NCT02579252
534,545,50-85 years,value,NCT02579252
736,766,acetylcholinesterase inhibitor,drug,NCT02579252
771,788,at least 3 months,time,NCT02579252
830,839,memantine,drug,NCT02579252
925,955,hachinski ischemia scale score,measurement,NCT02579252
956,959,≤ 4,value,NCT02579252
979,988,caregiver,caregiver,NCT02579252
990,1074,female patients must be either surgically sterile or at least 2 years postmenopausal,condition,NCT02579252
992,996,male,demography,NCT02579252
1043,1059,at least 2 years,time,NCT02579252
1076,1238,"male patients must either be surgically sterile, or he and his female spouse/partner who is of childbearing potential must be using highly effective contraception",condition,NCT02579252
20,45,mild cognitive impairment,condition,NCT02646982
131,238,"logical memory subscale (delayed paragraph recall, paragraph a only) from the wechsler memory scale-revised",measurement,NCT02646982
267,366,<11 for 16 or more years of education; <9 for 8-15 years of education; <6 for <7 years of education,value,NCT02646982
295,304,education,demography,NCT02646982
368,404,montreal cognitive assessment (moca),measurement,NCT02646982
405,409,< 26,value,NCT02646982
410,434,clinical dementia rating,measurement,NCT02646982
419,427,dementia,condition,NCT02646982
561,579,amyloid positivity,value,NCT02646982
671,690,cerebrospinal fluid,measurement,NCT02646982
692,695,csf,measurement,NCT02646982
717,739,amyloid scan (pib-pet),procedure,NCT02646982
34,75,early signs of dementia of alzheimer type,condition,NCT02788513
76,80,male,demography,NCT02788513
109,112,age,demography,NCT02788513
116,133,at least 55 years,value,NCT02788513
153,184,acetylcholinesterase inhibitors,drug,NCT02788513
186,192,acheis,drug,NCT02788513
197,221,allowed but not required,value,NCT02788513
327,344,at least 3 months,time,NCT02788513
609,616,stopped,value,NCT02788513
674,690,at least 6 years,value,NCT02788513
694,710,formal education,demography,NCT02788513
853,866,study partner,caregiver,NCT02788513
911,948,"family member, partner etc., guardian",caregiver,NCT02788513
248,261,men and women,demography,NCT02907567
263,274,50-80 years,value,NCT02907567
278,281,age,demography,NCT02907567
305,307,no,value,NCT02907567
314,350,mild to moderate alzheimer's disease,condition,NCT02907567
381,536,"women must be neither pregnant nor nursing, and are either surgically sterile, postmenopausal or premenopausal using an acceptable method of contraception.",condition,NCT02907567
593,611,neuroimaging (mri),procedure,NCT02907567
607,610,mri,measurement,NCT02907567
671,732,consistent with the clinical diagnosis of alzheimer's disease,value,NCT02907567
734,738,mmse,measurement,NCT02907567
739,744,18-26,value,NCT02907567
783,815,geriatric depression score (gds),measurement,NCT02907567
819,822,< 6,value,NCT02907567
824,842,modified hachinski,measurement,NCT02907567
858,861,≤ 4,value,NCT02907567
863,879,formal education,demography,NCT02907567
883,902,eight or more years,value,NCT02907567
904,994,living at home or in a community setting (assisted living) without continuous nursing care,demography,NCT02907567
1030,1039,caregiver,caregiver,NCT02907567
1054,1077,at least 3 times weekly,time,NCT02907567
1306,1337,acetylcholinesterase inhibitors,drug,NCT02907567
1341,1350,memantine,drug,NCT02907567
1366,1383,for 90 days prior,time,NCT02907567
20,32,man or women,demography,NCT02997982
34,37,age,demography,NCT02997982
38,48,≥ 65 years,value,NCT02997982
178,182,mmse,measurement,NCT02997982
234,236,no,value,NCT02997982
266,285,alzheimer's disease,condition,NCT02997982
289,314,mild cognitive impairment,condition,NCT02997982
343,355,at least one,value,NCT02997982
356,369,brain imaging,procedure,NCT02997982
405,428,"ct, mr, spect or pet/ct",procedure,NCT02997982
527,610,"reduced perfusion or reduced metabolism bilaterally temporally, hippocampal atrophy",value,NCT02997982
614,658,pathological markers for alzheimer's disease,value,NCT02997982
662,681,cerebrospinal fluid,measurement,NCT02997982
868,874,normal,value,NCT02997982
906,914,positive,value,NCT02997982
919,983,anti-hsv (herpes simplex virus) immunoglobulin g (igg) in plasma,measurement,NCT02997982
1006,1026,hetero or homozygote,value,NCT02997982
1031,1062,allele 4 of gene apolipoprotein,measurement,NCT02997982
1038,1039,4,value,NCT02997982
1139,1151,rivastigmine,drug,NCT02997982
1153,1163,galantamin,drug,NCT02997982
1165,1174,donepezil,drug,NCT02997982
1178,1186,memantin,drug,NCT02997982
1192,1210,at least one month,time,NCT02997982
1212,1281,no known allergy or oversensitivity against valaciclovir or aciclovir,condition,NCT02997982
1327,1335,relative,caregiver,NCT02997982
1345,1354,caretaker,caregiver,NCT02997982
36,85,gradual and progressive change in memory function,condition,NCT03352557
91,109,more than 6 months,time,NCT03352557
154,179,mild cognitive impairment,condition,NCT03352557
193,212,alzheimer's disease,condition,NCT03352557
221,228,mild ad,condition,NCT03352557
299,323,clinical dementia rating,measurement,NCT03352557
308,316,dementia,condition,NCT03352557
331,334,cdr,measurement,NCT03352557
352,355,0.5,value,NCT03352557
360,373,mci due to ad,condition,NCT03352557
377,385,0.5 or 1,value,NCT03352557
398,434,mini-mental state examination (mmse),measurement,NCT03352557
444,452,22 to 30,value,NCT03352557
465,485,cdr memory box score,measurement,NCT03352557
489,493,≥0.5,value,NCT03352557
528,532,apoe,measurement,NCT03352557
557,566,informant,caregiver,NCT03352557
567,580,study partner,caregiver,NCT03352557
591,614,amyloid beta positivity,condition,NCT03352557
43,51,dementia,condition,NCT03363269
105,125,probable alzheimer's,condition,NCT03363269
164,182,modified hachinski,measurement,NCT03363269
207,230,less than or equal to 4,value,NCT03363269
231,266,mini-mental state examination score,measurement,NCT03363269
267,275,16 to 26,value,NCT03363269
280,304,clinical dementia rating,measurement,NCT03363269
324,327,0.5,value,NCT03363269
333,349,amyloid postivie,value,NCT03363269
350,359,pet image,procedure,NCT03363269
361,378,bapl score 2 or 3,value,NCT03363269
411,426,ache inhibitors,drug,NCT03363269
430,445,nmda antagonist,drug,NCT03363269
446,467,at least for 3 months,time,NCT03363269
20,69,gradual and progressive change in memory function,condition,NCT03367403
98,108,informants,caregiver,NCT03367403
113,123,≥ 6 months,time,NCT03367403
125,129,mmse,measurement,NCT03367403
139,147,20 to 28,value,NCT03367403
200,221,flortaucipir pet scan,procedure,NCT03367403
222,237,within 6 months,time,NCT03367403
20,44,diagnosis of probable ad,value,NCT03520998
33,44,probable ad,condition,NCT03520998
130,134,mmse,measurement,NCT03520998
141,146,12-24,value,NCT03520998
157,175,modified hachinski,measurement,NCT03520998
207,210,≤ 4,value,NCT03520998
298,318,legal representative,caregiver,NCT03520998
334,347,trial partner,caregiver,NCT03520998
20,24,ages,demography,NCT03533257
25,30,55-89,value,NCT03533257
43,47,male,demography,NCT03533257
62,64,no,value,NCT03533257
71,91,probable alzheimer's,condition,NCT03533257
103,128,mild cognitive impairment,condition,NCT03533257
252,254,ad,condition,NCT03533257
300,304,moca,measurement,NCT03533257
305,311,8 - 26,value,NCT03533257
402,428,geriatric depression scale,measurement,NCT03533257
429,431,<7,value,NCT03533257
444,460,able to complete,value,NCT03533257
498,614,"not pregnant, lactating or of child-bearing potential (women must be >2 years post-menopausal or surgically sterile)",condition,NCT03533257
615,628,study partner,caregiver,NCT03533257
634,660,at least two days per week,time,NCT03533257
853,907,biomarker supportive of ad as the underlying pathology,value,NCT03533257
950,961,amyloid pet,procedure,NCT03533257
963,966,csf,measurement,NCT03533257
982,989,fdg-pet,procedure,NCT03533257
994,1003,vmri scan,procedure,NCT03533257
1010,1034,cholinesterase inhibitor,drug,NCT03533257
1042,1051,memantine,drug,NCT03533257
1070,1082,for 3 months,time,NCT03533257
33,36,age,demography,NCT03656042
40,87,at lease 50 years old and no more than 85 years,value,NCT03656042
58,61,old,demography,NCT03656042
113,132,alzheimer's disease,condition,NCT03656042
229,237,dementia,condition,NCT03656042
409,410,1,value,NCT03656042
419,436,ct/mri brain scan,procedure,NCT03656042
422,425,mri,measurement,NCT03656042
437,457,supporting evidences,value,NCT03656042
472,509,mini-mental examination (mmse) scores,measurement,NCT03656042
513,521,12 to 26,value,NCT03656042
548,572,clinical dementia rating,measurement,NCT03656042
574,577,cdr,measurement,NCT03656042
588,611,1 (mild) or 2 moderate),value,NCT03656042
626,644,modified hachinski,measurement,NCT03656042
663,664,4,value,NCT03656042
681,735,hamilton psychiatric rating scale for depression score,measurement,NCT03656042
743,986,female subject with child-bearing potential agrees to take reliable contraceptive method during the participation of the study (females with no child-bearing potential have to be surgically sterilized or at least 2 years after post-menopausal),condition,NCT03656042
947,963,at least 2 years,time,NCT03656042
1092,1101,caregiver,caregiver,NCT03656042
20,23,age,demography,NCT04063124
24,41,65 years or above,value,NCT04063124
56,58,no,value,NCT04063124
65,67,ad,condition,NCT04063124
69,73,moca,measurement,NCT04063124
74,79,10-20,value,NCT04063124
84,108,clinical dementia rating,measurement,NCT04063124
93,101,dementia,condition,NCT04063124
115,118,cdr,measurement,NCT04063124
144,169,cholinesterase inhibitors,drug,NCT04063124
174,195,at least three months,time,NCT04063124
179,182,ast,measurement,NCT04063124
196,217,body mass index (bmi),measurement,NCT04063124
234,248,19 - 35 kg/ m2,value,NCT04063124
255,261,normal,value,NCT04063124
262,279,blood cell counts,measurement,NCT04063124
323,327,wbcs,measurement,NCT04063124
329,351,"4,500-10,500 cells/mcl",value,NCT04063124
353,378,absolute neutrophil count,measurement,NCT04063124
380,401,"1,800-8,700 cells/mcl",value,NCT04063124
403,412,platelets,measurement,NCT04063124
414,426,140-450 k/ul,value,NCT04063124
428,438,hemoglobin,measurement,NCT04063124
439,457,12.0-17.5 grams/dl,value,NCT04063124
460,465,liver,measurement,NCT04063124
470,484,renal function,measurement,NCT04063124
490,500,10-40 iu/l,value,NCT04063124
502,517,total bilirubin,measurement,NCT04063124
518,531,0.1-1.4 mg/dl,value,NCT04063124
534,545,cholesterol,measurement,NCT04063124
547,557,<240 mg/dl,value,NCT04063124
560,573,triglycerides,measurement,NCT04063124
575,585,<300 mg/dl,value,NCT04063124
609,614,hba1c,measurement,NCT04063124
615,618,< 7,value,NCT04063124
622,632,pt/ptt/inr,measurement,NCT04063124
633,653,within normal limits,value,NCT04063124
692,725,legally authorized representative,caregiver,NCT04063124
777,790,study partner,caregiver,NCT04063124
20,24,ages,demography,NCT04079803
25,46,>= 50 and <= 85 years,value,NCT04079803
157,165,dementia,condition,NCT04079803
185,205,probable alzheimer's,condition,NCT04079803
214,249,mini-mental state examination score,measurement,NCT04079803
250,265,>= 16 and <= 26,value,NCT04079803
282,304,"female, postmenopausal",condition,NCT04079803
309,324,at least 1 year,time,NCT04079803
333,461,"living at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-h) nursing care",demography,NCT04079803
588,597,memantine,drug,NCT04079803
599,611,rivastigmine,drug,NCT04079803
613,624,galantamine,drug,NCT04079803
631,636,achei,drug,NCT04079803
666,683,at least 3 months,time,NCT04079803
698,707,donepezil,drug,NCT04079803
718,745,lower than 23 mg once daily,value,NCT04079803
740,745,daily,time,NCT04079803
764,774,non-smoker,condition,NCT04079803
779,795,at least 3 years,time,NCT04079803
812,832,legal representative,caregiver,NCT04079803
899,914,lumbar puncture,procedure,NCT04079803
934,953,cerebrospinal fluid,measurement,NCT04079803
981,1035,ratio of total tau/aβ42 in cerebrospinal fluid >= 0.28,value,NCT04079803
1051,1060,caregiver,caregiver,NCT04079803
41,45,ages,demography,NCT04187547
49,58,50 and 85,value,NCT04187547
102,103,1,value,NCT04187547
114,128,86 to 90 years,value,NCT04187547
292,300,dementia,condition,NCT04187547
348,352,mmse,measurement,NCT04187547
367,375,14 to 26,value,NCT04187547
420,422,no,value,NCT04187547
448,468,probable alzheimer's,condition,NCT04187547
570,596,magnetic resonance imaging,procedure,NCT04187547
643,667,diagnosis of probable ad,value,NCT04187547
656,667,probable ad,condition,NCT04187547
669,737,fluorodeoxyglucose positron emission tomography (fdg-pet) brain scan,procedure,NCT04187547
748,770,pattern typical for ad,value,NCT04187547
959,963,apoe,measurement,NCT04187547
964,981,negative genotype,value,NCT04187547
1013,1023,laboratory,measurement,NCT04187547
1115,1140,cholinesterase inhibitors,drug,NCT04187547
1149,1158,donepezil,drug,NCT04187547
1160,1171,galantamine,drug,NCT04187547
1176,1188,rivastigmine,drug,NCT04187547
1197,1203,gv-971,drug,NCT04187547
1212,1221,memantine,drug,NCT04187547
1229,1331,"other agents which may impact cognition (e.g., souvenaid®, neuroaidtm, cerefolin®, gingko biloba, etc)",drug,NCT04187547
1419,1431,for 3 months,time,NCT04187547
1531,1536,daily,time,NCT04187547
1672,1679,tacrine,drug,NCT04187547
1687,1698,not allowed,time,NCT04187547
1877,1948,do not have active suicidal thoughts (answers 'yes' to questions 4 or 5,value,NCT04187547
1957,2005,columbia-suicide severity rating scale [c-ssrs]),measurement,NCT04187547
2006,2021,within 6 months,time,NCT04187547
2101,2137,no active history of suicide attempt,condition,NCT04187547
2145,2161,previous 2 years,time,NCT04187547
2165,2201,more than 1 lifetime suicide attempt,condition,NCT04187547
2397,2406,caregiver,caregiver,NCT04187547
24,60,female of non-childbearing potential,demography,NCT04191486
70,74,ages,demography,NCT04191486
75,89,50 to 80 years,value,NCT04191486
102,115,mci due to ad,condition,NCT04191486
119,126,mild ad,condition,NCT04191486
184,188,mmse,measurement,NCT04191486
189,197,24 to 30,value,NCT04191486
210,213,csf,measurement,NCT04191486
235,339,"consistent with the presence of aß and p-tau181 abnormality (≤1000 pg/ml for aß, ≥19 pg/ml for p-tau181)",value,NCT04191486
363,418,"ache inhibitor (donepezil, galantamine or rivastigmine)",drug,NCT04191486
419,440,at least for 3 months,time,NCT04191486
483,498,ache inhibitors,drug,NCT04191486
20,24,aged,demography,NCT04249869
25,38,over 65 years,value,NCT04249869
39,42,old,demography,NCT04249869
43,63,regardless of gender,demography,NCT04249869
89,98,caregiver,caregiver,NCT04249869
316,358,mild to moderate alzheimer's type dementia,condition,NCT04249869
360,364,mmse,measurement,NCT04249869
379,388,14 and 26,value,NCT04249869
425,438,over 3 months,time,NCT04249869
450,480,acetylcholinesterase inhibitor,drug,NCT04249869
482,506,nmda receptor antagonist,drug,NCT04249869
512,526,antipsychotics,drug,NCT04249869
528,543,antidepressants,drug,NCT04249869
545,560,mood stabilizer,drug,NCT04249869
566,583,anxiolytic agents,drug,NCT04249869
113,116,age,demography,NCT04263519
117,122,55-85,value,NCT04263519
134,138,male,demography,NCT04263519
163,188,mci or dementia due to ad,condition,NCT04263519
201,209,positive,value,NCT04263519
210,244,ad biomarker (csf or neuroimaging),procedure,NCT04263519
224,227,csf,measurement,NCT04263519
246,255,education,demography,NCT04263519
326,342,able to complete,value,NCT04263519
450,466,lumbar punctures,procedure,NCT04263519
468,472,mris,procedure,NCT04263519
512,525,study partner,caregiver,NCT04263519
531,568,at least two days of contact per week,time,NCT04263519
637,661,cholinesterase inhibitor,drug,NCT04263519
669,678,memantine,drug,NCT04263519
697,709,for 3 months,time,NCT04263519
29,100,completion of participation in the anavex2-73-ad-004 double-blind study,condition,NCT04314934
80,81,4,value,NCT04314934
129,140,outpatients,demography,NCT04314934
145,185,residents of an assisted-living facility,demography,NCT04314934
223,236,study partner,caregiver,NCT04314934
249,272,at least 10hrs per week,time,NCT04314934
326,331,carer,caregiver,NCT04314934
376,378,no,value,NCT04314934
405,440,no suicidal ideation of type 4 or 5,value,NCT04314934
448,495,columbia suicide severity rating scale (c-ssrs),measurement,NCT04314934
508,516,3 months,time,NCT04314934
644,661,suicidal behavior,condition,NCT04314934
669,681,past 2 years,time,NCT04314934
816,892,if of childbearing potential is not pregnant through urine pregnancy testing,condition,NCT04314934
24,27,age,demography,NCT04491006
28,42,55 to 85 years,value,NCT04491006
43,71,mild-to-moderate ad dementia,condition,NCT04491006
82,86,mmse,measurement,NCT04491006
87,92,14-24,value,NCT04491006
94,97,cdr,measurement,NCT04491006
98,104,1 or 2,value,NCT04491006
140,168,"dementia, due probably to ad",condition,NCT04491006
279,303,support person/caregiver,caregiver,NCT04491006
339,369,acetylcholinesterase inhibitor,drug,NCT04491006
371,376,achei,drug,NCT04491006
467,507,achei (except for donepezil at 23 mg po),drug,NCT04491006
512,529,at least 3 months,time,NCT04491006
512,536,at least 3 months before,value,NCT04491006
597,623,discontinued 4 weeks prior,time,NCT04491006
20,39,mild to moderate ad,condition,NCT04520412
101,116,at least 1 year,time,NCT04520412
110,111,1,value,NCT04520412
118,122,mmse,measurement,NCT04520412
138,147,11 and 24,value,NCT04520412
173,182,brain mri,procedure,NCT04520412
179,182,mri,measurement,NCT04520412
188,222,show the highest possibility of ad,value,NCT04520412
231,244,study partner,caregiver,NCT04520412
245,254,caregiver,caregiver,NCT04520412
20,23,age,demography,NCT04570085
24,28,≥ 50,value,NCT04570085
42,69,probable alzheimer dementia,condition,NCT04570085
187,200,brain imaging,procedure,NCT04570085
208,211,mri,measurement,NCT04570085
208,211,mri,procedure,NCT04570085
217,321,"blood test (including ionogram, kidney and liver function, calcemia, crp, tsh, b12 vitamins and folates)",measurement,NCT04570085
348,352,mmse,measurement,NCT04570085
359,362,≥16,value,NCT04570085
378,387,informant,caregiver,NCT04570085
392,401,caregiver,caregiver,NCT04570085
403,426,living with the patient,time,NCT04570085
427,432,iache,drug,NCT04570085
440,449,memantine,drug,NCT04570085
528,536,2 months,time,NCT04570085
20,40,probable alzheimer's,condition,NCT04592341
50,52,ad,condition,NCT04592341
54,62,dementia,condition,NCT04592341
66,78,prodromal ad,condition,NCT04592341
107,120,study partner,caregiver,NCT04592341
139,148,caregiver,caregiver,NCT04592341
317,320,mri,measurement,NCT04592341
317,320,mri,procedure,NCT04592341
347,358,pet imaging,procedure,NCT04592341
575,610,evidence of ad pathological process,value,NCT04592341
628,639,amyloid pet,procedure,NCT04592341
689,699,laboratory,measurement,NCT04592341
761,797,mini-mental state examination (mmse),measurement,NCT04592341
804,809,>/=22,value,NCT04592341
814,838,clinical dementia rating,measurement,NCT04592341
853,856,cdr,measurement,NCT04592341
864,867,0.5,value,NCT04592341
871,872,1,value,NCT04592341
889,919,clinical dementia rating (cdr),measurement,NCT04592341
980,1006,symptomatic ad medications,drug,NCT04592341
1036,1053,at least 3 months,time,NCT04592341
1410,1541,women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods,condition,NCT04592341
20,32,both genders,demography,NCT04629495
37,54,all ethnic groups,demography,NCT04629495
55,59,ages,demography,NCT04629495
60,74,55 to 89 years,value,NCT04629495
88,97,mci or ad,condition,NCT04629495
98,135,(mini mental status examination (mmse,measurement,NCT04629495
138,143,18-30,value,NCT04629495
145,169,clinical dementia rating,measurement,NCT04629495
154,162,dementia,condition,NCT04629495
177,180,cdr,measurement,NCT04629495
184,187,0.5,value,NCT04629495
193,254,california verbal learning test iii (cvlt-iii) delayed recall,measurement,NCT04629495
255,287,≤16% based on age-adjusted norms,value,NCT04629495
309,327,amyloid positivity,value,NCT04629495
337,348,amyloid pet,procedure,NCT04629495
363,369,normal,value,NCT04629495
370,387,blood cell counts,measurement,NCT04629495
438,443,liver,measurement,NCT04629495
448,462,renal function,measurement,NCT04629495
485,490,hba1c,measurement,NCT04629495
491,497,< 6.5%,value,NCT04629495
500,519,fasting lipid panel,measurement,NCT04629495
524,607,prothrombin time/prothrombin time test/international normalized ration (pt/ptt/inr),measurement,NCT04629495
608,628,within normal limits,value,NCT04629495
631,664,legally authorized representative,caregiver,NCT04629495
868,877,donepezil,drug,NCT04629495
879,891,rivastigmine,drug,NCT04629495
893,902,memantine,drug,NCT04629495
904,915,galantamine,drug,NCT04629495
921,942,at least three months,time,NCT04629495
32,33,1,value,NCT04639050
150,163,study partner,caregiver,NCT04639050
452,478,magnetic resonance imaging,procedure,NCT04639050
480,483,mri,measurement,NCT04639050
480,483,mri,procedure,NCT04639050
486,501,lumbar puncture,procedure,NCT04639050
528,562,positron emission tomography [pet],procedure,NCT04639050
657,659,ad,condition,NCT04639050
824,861,probable mild to moderate ad dementia,condition,NCT04639050
967,978,probable ad,condition,NCT04639050
992,1004,prodromal ad,condition,NCT04639050
1072,1097,mild cognitive impairment,condition,NCT04639050
1119,1155,mini-mental state examination (mmse),measurement,NCT04639050
1165,1173,18 to 28,value,NCT04639050
1201,1202,4,value,NCT04639050
1224,1248,clinical dementia rating,measurement,NCT04639050
1263,1266,cdr,measurement,NCT04639050
1274,1277,0.5,value,NCT04639050
1318,1326,positive,value,NCT04639050
1327,1338,amyloid pet,procedure,NCT04639050
1354,1373,>50 centiloid units,value,NCT04639050
1375,1391,within 12 months,time,NCT04639050
1434,1460,symptomatic ad medications,drug,NCT04639050
1808,1812,apoe,measurement,NCT04639050
51,62,both gender,demography,NCT04780399
193,204,probable ad,condition,NCT04780399
210,221,body weight,measurement,NCT04780399
233,240,45-90kg,value,NCT04780399
242,246,aged,demography,NCT04780399
247,266,≥ 65 and ≤ 85 years,value,NCT04780399
267,270,old,demography,NCT04780399
314,318,mmse,measurement,NCT04780399
328,341,15 through 26,value,NCT04780399
367,370,mri,measurement,NCT04780399
367,370,mri,procedure,NCT04780399
407,439,confirmed with a diagnosis of ad,value,NCT04780399
441,475,medial temporal atrophy scale (mta,measurement,NCT04780399
560,638,"≥1.5 (adjusted by age: 65-74 years ≥ 1.5 points, 75-84 years old ≥ 2.0 points)",value,NCT04780399
646,658,pib-pet scan,procedure,NCT04780399
662,665,csf,measurement,NCT04780399
673,722,consistent with the presence of amyloid pathology,value,NCT04780399
833,839,normal,value,NCT04780399
908,917,caregiver,caregiver,NCT04780399
20,36,males or females,demography,NCT04902703
45,48,age,demography,NCT04902703
49,64,60 and 80 years,value,NCT04902703
114,131,partner/caregiver,caregiver,NCT04902703
132,141,informant,caregiver,NCT04902703
183,207,at least 12 hours a week,time,NCT04902703
414,416,ad,condition,NCT04902703
736,746,laboratory,measurement,NCT04902703
767,778,probable ad,condition,NCT04902703
779,787,dementia,condition,NCT04902703
949,956,mild ad,condition,NCT04902703
973,977,moca,measurement,NCT04902703
987,992,10-22,value,NCT04902703
1009,1017,positive,value,NCT04902703
1068,1071,csf,measurement,NCT04902703
1140,1145,achei,drug,NCT04902703
1175,1192,at least 2 months,time,NCT04902703
1200,1224,cholinesterase inhibitor,drug,NCT04902703
1232,1241,memantine,drug,NCT04902703
42,61,alzheimer's disease,condition,NCT05006781
65,90,mild cognitive impairment,condition,NCT05006781
91,95,mmse,measurement,NCT05006781
104,109,10-26,value,NCT05006781
110,113,cdr,measurement,NCT05006781
114,122,1 or 0.5,value,NCT05006781
20,69,gradual and progressive change in memory function,condition,NCT05063539
98,108,informants,caregiver,NCT05063539
113,123,≥ 6 months,time,NCT05063539
124,128,mmse,measurement,NCT05063539
138,146,22 to 30,value,NCT05063539
171,174,cdr,measurement,NCT05063539
191,194,0.5,value,NCT05063539
239,243,≥0.5,value,NCT05063539
250,306,18f flortaucipir positron emission tomography (pet) scan,procedure,NCT05063539
342,355,study partner,caregiver,NCT05063539
20,24,male,demography,NCT05104463
44,48,≥ 50,value,NCT05104463
67,70,age,demography,NCT05104463
113,138,mild cognitive impairment,condition,NCT05104463
147,155,dementia,condition,NCT05104463
248,256,positive,value,NCT05104463
304,305,1,value,NCT05104463
339,358,alzheimer's disease,condition,NCT05104463
360,362,ad,condition,NCT05104463
385,413,anti-parkinsonian medication,drug,NCT05104463
422,427,daily,time,NCT05104463
439,455,at least 1 month,time,NCT05104463
531,614,"single drug for ad (e.g., donepezil or other cholinesterase inhibitors or memantine",drug,NCT05104463
684,701,at least 2 months,time,NCT05104463
900,953,alternative causes of cognitive decline are ruled out,condition,NCT05104463
1069,1088,spouse or caregiver,caregiver,NCT05104463
1199,1278,greater than or equal to one standard deviation below age and educational norms,value,NCT05104463
1286,1323,digit symbol substitution test (dsst),measurement,NCT05104463
1344,1359,within 6 months,time,NCT05104463
1380,1416,montreal cognitive assessment (moca),measurement,NCT05104463
1423,1436,≥ 18 and ≤ 26,value,NCT05104463
1527,1553,magnetic resonance imaging,procedure,NCT05104463
1558,1561,mri,measurement,NCT05104463
1558,1561,mri,procedure,NCT05104463
2072,2506,"females of childbearing potential (i.e., not postmenopausal or surgically sterile) who have a male partner must have a negative serum pregnancy test result and must agree to one of the following from start of screening through 30 days after the last study medication administration: use a highly effective method of birth control; or monogamous relationship with a male partner of confirmed sterility; or practice complete abstinence.",condition,NCT05104463
2515,2609,of non-childbearing potential may be enrolled if it is documented that they are postmenopausal,condition,NCT05104463
2611,2622,body weight,measurement,NCT05104463
2623,2648,greater or equal to 50 kg,value,NCT05104463
2653,2674,body mass index (bmi),measurement,NCT05104463
2683,2698,18 and 35 kg/m2,value,NCT05104463
2750,2762,for 3 months,time,NCT05104463
20,45,mild cognitive impairment,condition,NCT05282550
165,189,clinical dementia rating,measurement,NCT05282550
174,182,dementia,condition,NCT05282550
191,194,cdr,measurement,NCT05282550
199,202,0.5,value,NCT05282550
271,301,pittsburgh sleep quality index,measurement,NCT05282550
311,313,>5,value,NCT05282550
375,393,memory performance,measurement,NCT05282550
394,472,> 1.5 standard deviation (sd) below age-and education-matched control subjects,value,NCT05282550
430,433,age,demography,NCT05282550
438,447,education,demography,NCT05282550
480,566,repeatable battery for the assessment of neuropsychological status (rbans) list recall,measurement,NCT05282550
636,655,good general health,condition,NCT05282550
661,663,no,value,NCT05282550
723,749,magnetic resonance imaging,procedure,NCT05282550
751,754,mri,measurement,NCT05282550
751,754,mri,procedure,NCT05282550
792,801,informant,caregiver,NCT05282550
29,33,aged,demography,NCT05303701
34,52,≥ 55 to ≤ 85 years,value,NCT05303701
99,101,no,value,NCT05303701
106,114,dementia,condition,NCT05303701
158,178,probable alzheimer's,condition,NCT05303701
212,214,ad,condition,NCT05303701
243,255,k-mmse score,measurement,NCT05303701
256,260,≤ 19,value,NCT05303701
298,330,gds (global deterioration scale),measurement,NCT05303701
331,343,grade 5 to 6,value,NCT05303701
362,411,no other diseases to cause dementia other than ad,value,NCT05303701
427,430,mri,measurement,NCT05303701
427,430,mri,procedure,NCT05303701
442,458,within 12 months,time,NCT05303701
508,517,donepezil,drug,NCT05303701
527,565,donepezil and memantine in combination,drug,NCT05303701
605,618,over 3 months,time,NCT05303701
668,719,subjects who can walk with or without assist device,condition,NCT05303701
807,816,caregiver,caregiver,NCT05303701
1064,1074,caregivers,caregiver,NCT05303701
105,129,mini-mental (mmse) score,measurement,NCT05463731
133,141,20 to 28,value,NCT05463731
174,179,p-tau,measurement,NCT05463731
187,236,consistent with the presence of amyloid pathology,value,NCT05463731
245,256,amyloid pet,procedure,NCT05463731
262,324,result consistent with the presence of brain amyloid pathology,value,NCT05463731
342,355,study partner,caregiver,NCT05463731
730,747,males and females,demography,NCT05463731
781,841,women not of childbearing potential (wnocbp) may participate,condition,NCT05463731
29,33,aged,demography,NCT05468073
34,38,> 18,value,NCT05468073
39,70,age of disease onset < 70 years,time,NCT05468073
108,110,ad,condition,NCT05468073
222,225,csf,measurement,NCT05468073
237,253,suggestive of ad,value,NCT05468073
255,264,brain mri,procedure,NCT05468073
261,264,mri,measurement,NCT05468073
265,293,congruent with the diagnosis,value,NCT05468073
340,343,cdr,measurement,NCT05468073
345,369,clinical dementia rating,measurement,NCT05468073
354,362,dementia,condition,NCT05468073
379,382,0.5,value,NCT05468073
408,422,antidepressant,drug,NCT05468073
426,457,acetylcholinesterase inhibitors,drug,NCT05468073
529,546,at least 3 months,time,NCT05468073
529,553,at least 3 months before,value,NCT05468073
572,581,caregiver,caregiver,NCT05468073
668,677,informant,caregiver,NCT05468073
22,24,ad,condition,NCT05476783
130,293,completed lead-in protocol tb006ad2102 (participants from both study drug and placebo groups) or are eligible for the lead-in study but were not enrolled (de novo),condition,NCT05476783
624,775,contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies,condition,NCT05476783
777,822,females must be of non-childbearing potential,condition,NCT05476783
779,783,male,demography,NCT05476783
840,849,caregiver,caregiver,NCT05476783
1443,1461,male and/or female,demography,NCT05476783
1462,1472,> 50 years,value,NCT05476783
1476,1479,age,demography,NCT05476783
1525,1536,body weight,measurement,NCT05476783
1540,1544,≥ 50,value,NCT05476783
1564,1585,body mass index (bmi),measurement,NCT05476783
1594,1639,18 and 35 kilograms per square meter (kg/m^2),value,NCT05476783
1652,1656,mmse,measurement,NCT05476783
1666,1676,24 or less,value,NCT05476783
1686,1696,ambulatory,condition,NCT05476783
1754,1765,probable ad,condition,NCT05476783
1856,1875,alzheimer's disease,condition,NCT05476783
2070,2078,dementia,condition,NCT05476783
20,24,male,demography,NCT05531526
48,52,aged,demography,NCT05531526
53,67,55 to 80 years,value,NCT05531526
124,149,mild cognitive impairment,condition,NCT05531526
158,166,dementia,condition,NCT05531526
183,185,ad,condition,NCT05531526
209,210,4,value,NCT05531526
330,344,within 3 years,time,NCT05531526
376,389,study partner,caregiver,NCT05531526
415,419,mmse,measurement,NCT05531526
426,453,greater than or equal to 20,value,NCT05531526
474,477,cdr,measurement,NCT05531526
495,498,0.5,value,NCT05531526
502,503,1,value,NCT05531526
524,535,rbans score,measurement,NCT05531526
536,606,less than or equal to 85 based on the delayed memory index (dmi) score,value,NCT05531526
635,661,magnetic resonance imaging,procedure,NCT05531526
663,666,mri,measurement,NCT05531526
663,666,mri,procedure,NCT05531526
778,888,findings consistent with the diagnosis of ad and without any other clinically significant comorbid pathologies,value,NCT05531526
889,921,confirmed amyloid beta pathology,value,NCT05531526
925,944,cerebrospinal fluid,measurement,NCT05531526
946,949,csf,measurement,NCT05531526
21,83,completed rethink-alz (pti-125-07) or refocus-alz (pti-125-06),condition,NCT05575076
123,158,consistent with alzheimer's disease,value,NCT05575076
139,158,alzheimer's disease,condition,NCT05575076
178,191,study partner,caregiver,NCT05575076
61,80,alzheimer's disease,condition,NCT05578443
24,26,no,value,NCT05686044
33,52,alzheimer's disease,condition,NCT05686044
94,105,probable ad,condition,NCT05686044
106,110,male,demography,NCT05686044
121,125,aged,demography,NCT05686044
126,133,55 - 85,value,NCT05686044
141,145,mmse,measurement,NCT05686044
146,151,14-24,value,NCT05686044
160,173,study partner,caregiver,NCT05686044
288,314,at least 10 hours per week,time,NCT05686044
388,684,"female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly)",condition,NCT05686044
710,717,4 weeks,time,NCT05686044
1756,1902,*non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start,condition,NCT05686044
1864,1876,at least one,value,NCT05686044
1904,1989,male participants must be sterile or sexually inactive or agree not to father a child,condition,NCT05686044
2771,2804,legally authorized representative,caregiver,NCT05686044
2990,3160,no evidence of current suicidal ideation or previous suicide attempt in the past 2 months as evaluated in the columbia suicide severity rating scale nor suicidal behavior,condition,NCT05686044
3071,3079,2 months,time,NCT05686044
3168,3181,past 6 months,time,NCT05686044
3245,3258,least 4 weeks,time,NCT05686044
3279,3304,cholinesterase inhibitors,drug,NCT05686044
3312,3321,memantine,drug,NCT05686044
3333,3359,anticonvulsant medications,drug,NCT05686044
3431,3467,mood-stabilizing psychotropic agents,drug,NCT05686044
3622,3641,good general health,condition,NCT05686044
20,23,age,demography,NCT05728736
24,35,60-80 years,value,NCT05728736
36,43,any sex,demography,NCT05728736
44,62,any race/ethnicity,demography,NCT05728736
63,106,mini-mental status examination score (mmse),measurement,NCT05728736
107,111,≥ 27,value,NCT05728736
112,120,positive,value,NCT05728736
121,145,plasma amyloid-beta test,measurement,NCT05728736
171,201,pittsburgh sleep quality index,measurement,NCT05728736
202,204,>5,value,NCT05728736
20,69,gradual and progressive change in memory function,condition,NCT05738486
101,110,informant,caregiver,NCT05738486
128,164,mini mental state examination (mmse),measurement,NCT05738486
174,182,20 to 28,value,NCT05738486
217,228,amyloid pet,procedure,NCT05738486
260,309,consistent with the presence of amyloid pathology,value,NCT05738486
20,83,completion of the planned treatment period in the al002-2 study,condition,NCT05744401
147,160,study partner,caregiver,NCT05744401
238,262,at least 10 hours a week,time,NCT05744401
33,53,probable alzheimer's,condition,NCT05771428
143,144,1,value,NCT05771428
157,193,mini-mental state examination (mmse),measurement,NCT05771428
203,211,20 to 26,value,NCT05771428
215,239,clinical dementia rating,measurement,NCT05771428
224,232,dementia,condition,NCT05771428
241,244,cdr,measurement,NCT05771428
262,265,0.5,value,NCT05771428
37,52,55 and 85 years,value,NCT05986721
53,56,old,demography,NCT05986721
72,91,good general health,condition,NCT05986721
173,195,eighth-grade education,demography,NCT05986721
182,184,ad,condition,NCT05986721
199,257,good work history sufficient to exclude mental retardation,condition,NCT05986721
455,468,study partner,caregiver,NCT05986721
762,775,mci due to ad,condition,NCT05986721
906,910,mmse,measurement,NCT05986721
926,935,24 and 30,value,NCT05986721
1128,1152,lower memory performance,value,NCT05986721
1134,1152,memory performance,measurement,NCT05986721
1166,1200,delayed recall portion of the islt,measurement,NCT05986721
1204,1228,clinical dementia rating,measurement,NCT05986721
1213,1221,dementia,condition,NCT05986721
1230,1233,cdr,measurement,NCT05986721
1244,1247,0.5,value,NCT05986721
1275,1280,≥ 0.5,value,NCT05986721
1294,1330,preserved activities of daily living,condition,NCT05986721
1318,1323,daily,time,NCT05986721
1350,1352,no,value,NCT05986721
1416,1469,alternative causes of cognitive decline are ruled out,condition,NCT05986721
1484,1505,blood-based biomarker,measurement,NCT05986721
1522,1540,amyloid positivity,value,NCT05986721
1549,1574,apolipoprotein e genotype,measurement,NCT05986721
1585,1619,not include one or more e4 alleles,value,NCT05986721
1686,1711,cholinesterase inhibitors,drug,NCT05986721
1716,1725,memantine,drug,NCT05986721
1756,1766,≥ 3 months,time,NCT05986721
1838,1866,estrogen replacement therapy,drug,NCT05986721
1868,1881,ginkgo biloba,drug,NCT05986721
1887,1896,vitamin e,drug,NCT05986721
1926,1935,≥ 4 weeks,time,NCT05986721
2036,2051,antidepressants,drug,NCT05986721
2056,2070,antipsychotics,drug,NCT05986721
2214,2217,mri,measurement,NCT05986721
2214,2217,mri,procedure,NCT05986721
2238,2269,no contraindications to the mri,condition,NCT05986721
2433,2437,apoe,measurement,NCT05986721
